Status:
COMPLETED
A Study of LY3461767 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3461767 and any side effects that might be associated with it. The study will also measure how much LY3461...
Eligibility Criteria
Inclusion
- Are healthy males, or females of non-child-bearing potential
- Have a body mass index of 18 to 35 kilograms per square meter (kg/m²)
- Have clinical laboratory tests within normal ranges as judged by investigator
- Have pulse rate and blood pressure within normal ranges as judged by investigator
Exclusion
- Have Troponin I results above the upper reference limit, and judged to be clinically significant by the investigator, at screening
- Have an abnormality in the 12-lead electrocardiogram (ECG) at screening
- Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders
- Regularly use known drugs of abuse
- Have donated blood of more than 450 milliliters (mL), or have participated in a clinical study that required similar blood volume collected within the past 3 months
- Have an average weekly alcohol intake that exceeds 7 units per week or are unwilling to stop alcohol consumption as required during the study
- Smoke more than 10 cigarettes per day
- Are current or former smokers with 30-pack-year smoking history
- Have a diagnosis or history of any malignancy
- Have not had appropriate cancer screening, in accordance with country specific guidance
Key Trial Info
Start Date :
June 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2021
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT04352114
Start Date
June 15 2020
End Date
January 13 2021
Last Update
February 5 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Inc
Daytona Beach, Florida, United States, 32117
2
Covance Dallas
Dallas, Texas, United States, 75247
3
Lilly Nus Centre for Clin Pharmacology
Singapore, Singapore, 138623